PubMed ID:
36920087
Public Release Type:
Journal
Publication Year: 2023
DOI:
https://doi.org/10.2337/dc22-2200
Authors:
Russell William E., Bundy Brian N., Anderson Mark S., Cooney Laura A., Gitelman Stephen E., Goland Robin S., Gottlieb Peter A., Greenbaum Carla J., Haller Michael J., Krischer Jeffrey P., Libman Ingrid M., Linsley Peter S., Long S. Alice, Lord Sandra M., Moore Daniel J., Moore Wayne V., Moran Antoinette M., Muir Andrew B., Raskin Philip, Skyler Jay S., Wentworth John M., Wherrett Diane K., Wilson Darrell M., Ziegler Anette-Gabriele, Herold Kevan C.
Request IDs:
22818
Studies:
The Environmental Determinants of Diabetes in the Young
Previous studies showed that inhibiting lymphocyte costimulation reduces declining β-cell function in individuals newly diagnosed with type 1 diabetes. We tested whether abatacept would delay or prevent progression of type 1 diabetes from normal glucose tolerance (NGT) to abnormal glucose tolerance (AGT) or to diabetes and the effects of treatment on immune and metabolic responses.